vertex pharmaceuticals - Search News

Vertex Pharmaceuticals Stock Jumps

Hosted on MSN · 14m

Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more than 20 years.

MarketWatch · 6h

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

US FDA approves Vertex's non-opioid painkiller

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator said on Thursday, offering a first-of-its-kind alternative to addictive opioid painkillers that have fueled a national crisis.

England, Vertex Pharmaceuticals and Sickle Cell Disease

Seeking Alpha · 5h

Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to treat sickle cell disease. Read more here.

Business Insider · 8h

Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with

The Bakersfield Californian · 9h

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).

35m

Vertex Pharmaceuticals price target raised to $545 from $520 at BMO Capital

BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...

4hon MSN

FDA Approves First New Non-Opiod Painkiller in Decades

Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.

5hon MSN

These Stocks Are Moving the Most Today: Apple, Intel, Visa, Deckers, Atlassian, Vertex, Exxon, and More

Apple stock rises after the tech giant posts better-than-expected earnings and guides for solid growth, while Intel’s ...

2h

Vertex Pharmaceuticals price target raised to $433 from $430 at Scotiabank

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $433 from $430 and keeps a Sector Perform rating on the shares.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results